Amgen
Amgen Inc. is an American biopharmaceutical enterprise that discovers, develops, manufactures, and delivers innovative human therapeutics for serious illnesses. The company focuses its operational activities across four core therapeutic areas: oncology and hematology, cardiovascular disease, general medicine, and rare inflammatory diseases. Its commercial product portfolio comprises widely used biologic medicines such as Enbrel for rheumatoid arthritis, Prolia and Xgeva for bone health, Repatha for cholesterol management, Otezla, and Tepezza. Principal revenue drivers consist of worldwide commercial sales of proprietary prescription biopharmaceuticals, alongside royalty income, technology licensing agreements, and corporate research collaborations. Amgen serves diverse end markets encompassing hospital networks, retail and specialty pharmacies, medical practitioners, and patients across health authority systems in North America, Europe, Asia-Pacific, and Latin America. The enterprise maintains a leading global position as one of the world's largest independent biotechnology companies by total annual revenue and market capitalization. Headquartered in Thousand Oaks, California, the company's common stock is listed on the Nasdaq Global Select Market under the ticker symbol AMGN.
117 of the funds FundTelligence covers report a position in Amgen.
- Legal name
- Amgen Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 117
- Exposure themes
- Multiple, Treatment, Women's Health
Funds holding Amgen
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 8.4 % (full portfolio disclosed, October 2026)
- Polar Capital Biotechnology Fund — Polar Capital · 5.7 % (largest positions only, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 4.73 % (full portfolio disclosed, September 2026)
- UBS Biotech Equity Fund — UBS · 3.4 % (largest positions only, September 2026)
- BGF World Healthscience Fund — BlackRock · 3.3 % (largest positions only, October 2026)
- DWS Invest CROCI US — DWS · 2.79 % (full portfolio disclosed, June 2026)
- Handelsbanken Helse Tema — Handelsbanken · 2.51 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 2.33 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 117 funds holding it.